德费里治疗改善了患有β-thalassaemia/HbE的患者的LDL的氧化状态
Ngan Thi Tran1,2, Pakawit Lerksaipheng3,4, Pranee Sutcharitchan5
1Pharmacology and Toxicology Program, Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.
Drugs in context
|December 12, 2025
概括
德费里 (L1) 治疗改善了低密度脂蛋白 (LDL) 的氧化状态,在患有β-thalassaemia/血红蛋白E (HbE) 的患者中. 这种铁化疗法保护LDL免受氧化损伤,可能降低心血管风险.
科学领域:
- 心血管医学 心血管医学
- 血液学 血液学 血液学
- 生物化学 生物化学
背景情况:
- 低密度脂蛋白 (LDL) 的氧化修饰与β-thalassaemia/hemoglobin E (HbE) 患者的心血管并发症有关.
- 铁化剂德费里 (L1) 可减少铁过载和氧化应激.
研究的目的:
- 评估Deferiprone (L1) 对 β-thalassaemia/HbE.患者的LDL氧化状态的保护作用.
主要方法:
- 29名β-thalassaemia/HbE患者接受了为期4周的洗,随后接受了4周和12周的L1治疗.
- 监测非转林结合的铁 (NTBI) 和氧化应激标志物 (TBARS,α-托哥菲醇).
- 在Cu2+诱导氧化后,使用NBD-Pen光探针评估LDL氧化易感性.
主要成果:
- L1 防止了α-托哥菲罗尔的耗尽,并保留了LDL脂质成分.
- 观察到酸反应性物质 (TBARS) 水平下降.
- 来自洗期的LDL表现出最高的氧化敏感性.
结论:
- 使用德费里 (L1) 的铁化疗显著改善了LDL的氧化状态.
- 在β-thalassaemia/HbE患者中,L1治疗对LDL氧化具有保护作用.
相关概念视频
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
236
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
236
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Disorders of Erythrocytes
2.0K
Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
2.0K
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293


